Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Bacterial Infections and Mycoses

Free Subscription Articles published in Am J Respir Crit Care Med Retrieve available abstracts of 53 articles: HTML format

Single Articles

November 2025
1. PARK K, Kim H, Huh HJ, Namkoong H, et al
   Novel Genetic Loci for Nontuberculous Mycobacterial Pulmonary Disease and Potential Protective Effect of Body Mass Index.
   Am J Respir Crit Care Med. 2025;211:2191-2202.
   PubMed     Abstract available
   
   
   October 2025
2. ALFFENAAR JC
   Isoniazid for Preventive Treatment among Contacts of Multidrug-Resistant Tuberculosis; Does It Make Sense?
   Am J Respir Crit Care Med. 2025 Oct 24. doi: 10.1164/rccm.202509-2319.
   PubMed    
   
   
   
3. YANG X, Tao S, Jin C
   Advancing Tuberculosis Care through Evidence-based Short-Course Regimens.
   Am J Respir Crit Care Med. 2025 Oct 24. doi: 10.1164/rccm.202507-1750.
   PubMed    
   
   
   September 2025
4. SOBOL R, Omar SV, Brown T, Joseph L, et al
   Transmission of Bedaquiline-resistant Mycobacterium tuberculosis in KwaZulu-Natal, South Africa.
   Am J Respir Crit Care Med. 2025 Sep 30. doi: 10.1164/rccm.202506-1489.
   PubMed     Abstract available
   
   
   
5. ORTEGA VE, Pienaar E, Escalante P
   Genetic Susceptibility to Non-Tuberculous Mycobacterial Pulmonary Disease, Is the Chicken or the Egg?
   Am J Respir Crit Care Med. 2025 Sep 25. doi: 10.1164/rccm.202508-1970.
   PubMed    
   
   
   
6. LOADER MI, Vasquez Alves SE, Vasquez Alves NL, Coronel J, et al
   IgE, Matrix Metalloproteinases, and Tuberculosis: Immunologic Consequences of Helminth Co-Infection.
   Am J Respir Crit Care Med. 2025 Sep 23. doi: 10.1164/rccm.202507-1710.
   PubMed    
   
   
   
7. MARTINEZ L, Campbell JI, Linde L, Boulahbal F, et al
   The Effectiveness of Isoniazid Preventive Treatment among Contacts of Multidrug-Resistant Tuberculosis: A Systematic Review and Individual-Participant Meta-Analysis.
   Am J Respir Crit Care Med. 2025 Sep 23. doi: 10.1164/rccm.202411-2340.
   PubMed     Abstract available
   
   
   
8. MENDELSOHN SC, Jackson GT, Wessels E, Beyers E, et al
   Oral Rinse versus Facemask Capture for Non-Sputum Diagnosis of Pulmonary Tuberculosis.
   Am J Respir Crit Care Med. 2025 Sep 12. doi: 10.1164/rccm.202506-1477.
   PubMed    
   
   
   
9. GORDHAN BG, Sewcharran A, Waja Z, Martinson N, et al
   Oral Rinse as an Alternative Diagnostic Specimen for Detection of Tuberculosis.
   Am J Respir Crit Care Med. 2025 Sep 12. doi: 10.1164/rccm.202503-0723.
   PubMed    
   
   
   July 2025
10. TRAUTH J, Laspoulas A, Dakischew O, Gentil K, et al
    Bedaquiline-Pretomanid-Linezolid as a Bridging Therapy for Adverse Events in Drug-Sensitive Tuberculosis.
    Am J Respir Crit Care Med. 2025 Jul 18. doi: 10.1164/rccm.202501-0150.
    PubMed    
    
    
    
11. HULL RC, Stobo J, Abo-Leyah H, Richardson H, et al
    Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomised, Double-Blind, Placebo-controlled, Phase III Trials (ORBIT 3 and ORBIT 4).
    Am J Respir Crit Care Med. 2025 Jul 15. doi: 10.1164/rccm.202501-0159.
    PubMed     Abstract available
    
    
    
12. MASIAS-LEON Y, Ruiz-Gonzalez CE, Nino-Meza OJ, Singh M, et al
    Dynamic (11)C-Para-Aminobenzoic Acid Positron Emission Tomography/Computed Tomography for Visualizing Pulmonary Mycobacteroides abscessus Infections.
    Am J Respir Crit Care Med. 2025;211:1253-1263.
    PubMed     Abstract available
    
    
    
13. PHILLIPS PPJ, Peloquin CA, Sterling TR, Kaur P, et al
    Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial.
    Am J Respir Crit Care Med. 2025;211:1277-1287.
    PubMed     Abstract available
    
    
    June 2025
14. SAUKKONEN J, Munsiff S, Winston C, Duarte R, et al
    Reply to Wilson et al.: The 4-Month HPMZ Treatment Regimen for Drug-Susceptible Pulmonary Tuberculosis - A Word of Caution.
    Am J Respir Crit Care Med. 2025.
    PubMed    
    
    
    
15. WILSON JW, Temesgen Z MD, Gaensbauer JG
    The 4-Month HPMZ Treatment Regimen for Drug-Susceptible Pulmonary Tuberculosis - A Word of Caution.
    Am J Respir Crit Care Med. 2025.
    PubMed    
    
    
    
16. XIA Y, Jiang W, Zhu X, Pan B, et al
    Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021.
    Am J Respir Crit Care Med. 2025;211:1007-1017.
    PubMed     Abstract available
    
    
    
17. MENZIES NA, Marks SM, Hsieh YL, Swartwood NA, et al
    Contribution of Posttuberculosis Sequelae to Life-Years Lost from Tuberculosis Disease in the United States, 2015-2019.
    Am J Respir Crit Care Med. 2025;211:1059-1068.
    PubMed     Abstract available
    
    
    May 2025
18. THOMSON RM, Wheeler N, Stockwell RE, Bryant J, et al
    Infection by Clonally Related Mycobacterium abscessus Isolates: The Role of Drinking Water.
    Am J Respir Crit Care Med. 2025;211:842-853.
    PubMed     Abstract available
    
    
    March 2025
19. JANSSEN S, Upton C, de Jager VR, van Niekerk C, et al
    Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and Beyond.
    Am J Respir Crit Care Med. 2025 Mar 21. doi: 10.1164/rccm.202408-1632.
    PubMed     Abstract available
    
    
    February 2025
20. RUMPF CH, Janssen T, Hait RJ, Romme K, et al
    Mucoid Staphylococcus aureus - Prevalence and Association with Lung Function in People with Cystic Fibrosis.
    Am J Respir Crit Care Med. 2025 Feb 7. doi: 10.1164/rccm.202407-1474.
    PubMed     Abstract available
    
    
    January 2025
21. SAUKKONEN JJ, Duarte R, Munsiff SS, Winston CA, et al
    Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2025;211:15-33.
    PubMed     Abstract available
    
    
    December 2024
22. DERENDINGER B, Mochizuki TK, Marcelo D, Shankar D, et al
    C-reactive Protein-based Screening of People with Tuberculosis Symptoms: A Diagnostic Accuracy Study.
    Am J Respir Crit Care Med. 2024 Dec 6. doi: 10.1164/rccm.202405-1000.
    PubMed     Abstract available
    
    
    November 2024
23. EPELBAUM O, Marinelli T, Haydour QS, Pennington KM, et al
    Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients. An Of fi cial American Thoracic Society Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2024 Nov 18. doi: 10.1164/rccm.202410-2045.
    PubMed     Abstract available
    
    
    
24. 
    Erratum: Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.
    Am J Respir Crit Care Med. 2024;210:1280.
    PubMed    
    
    
    September 2024
25. LORE NI, Gramegna A, de Pretis S, Di Marco F, et al
    Single-Cell RNA Sequencing Shows that Circulating Monocytes Enriched in IFN Signaling Are Associated with Nontuberculous Mycobacteria Pulmonary Disease in Cystic Fibrosis.
    Am J Respir Crit Care Med. 2024;210:834-837.
    PubMed    
    
    
    August 2024
26. MORGAN SJ, Nichols DP, Ni W, Hong G, et al
    Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces Aspergillus fumigatus in Cystic Fibrosis.
    Am J Respir Crit Care Med. 2024 Aug 27. doi: 10.1164/rccm.202406-1128.
    PubMed    
    
    
    
27. ZAVALA S, Stout JE
    A Balancing Act: Finding the Right Dose of Pyrazinamide to Treat Tuberculosis.
    Am J Respir Crit Care Med. 2024 Aug 22. doi: 10.1164/rccm.202406-1262.
    PubMed    
    
    
    
28. AULD SC, Barczak AK, Bishai W, Coussens AK, et al
    Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the 2(nd) International Post-Tuberculosis Symposium.
    Am J Respir Crit Care Med. 2024 Aug 14. doi: 10.1164/rccm.202402-0374.
    PubMed     Abstract available
    
    
    
29. ROCHE SM, Ottewill C, Mulpeter R, Brown K, et al
    Delayed Tuberculosis Paradoxical Reaction Associated with TNF Inhibitors.
    Am J Respir Crit Care Med. 2024 Aug 12. doi: 10.1164/rccm.202402-0464.
    PubMed    
    
    
    July 2024
30. COHEN T, Colijn C, Warren JL
    Approaches for M. tuberculosis Transmission Inference Based on Genomic Data.
    Am J Respir Crit Care Med. 2024 Jul 17. doi: 10.1164/rccm.202404-0835.
    PubMed    
    
    
    
31. LEE WC
    Pairs or Paradoxes: Questioning Assumptions in Tuberculosis Transmission Research.
    Am J Respir Crit Care Med. 2024 Jul 17. doi: 10.1164/rccm.202405-0958.
    PubMed    
    
    
    
32. XU AY, Velasquez GE, Zhang N, Chang VK, et al
    Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial.
    Am J Respir Crit Care Med. 2024 Jul 16. doi: 10.1164/rccm.202401-0165.
    PubMed     Abstract available
    
    
    
33. MOSSOP M, Ish-Horowicz J, Hughes D, Dobra R, et al
    Chronicity Counts: The Impact of Pseudomonas aeruginosa, Staphylococcus aureus, and Coinfection in Cystic Fibrosis.
    Am J Respir Crit Care Med. 2024;210:240-242.
    PubMed    
    
    
    June 2024
34. CRABBE A
    Intracellular Pseudomonas aeruginosa: An Overlooked Reservoir in the Lungs of People with Cystic Fibrosis?
    Am J Respir Crit Care Med. 2024;209:1421-1423.
    PubMed    
    
    
    
35. MALET K, Faure E, Adam D, Donner J, et al
    Intracellular Pseudomonas aeruginosa within the Airway Epithelium of Cystic Fibrosis Lung Tissues.
    Am J Respir Crit Care Med. 2024;209:1453-1462.
    PubMed     Abstract available
    
    
    
36. FEYS S, Cardinali-Benigni M, Lauwers HM, Jacobs C, et al
    Profiling Bacteria in the Lungs of Patients with Severe Influenza Versus COVID-19 with or without Aspergillosis.
    Am J Respir Crit Care Med. 2024 Jun 12. doi: 10.1164/rccm.202401-0145.
    PubMed     Abstract available
    
    
    May 2024
37. ZHANG M, Yang C, Guo Y
    Aspergilloma in Cavity.
    Am J Respir Crit Care Med. 2024 May 31. doi: 10.1164/rccm.202312-2348.
    PubMed    
    
    
    
38. CRABBE A
    Moving Beyond Antibiotics: Exploring the Potential of an Anti-Virulence Monoclonal Antibody Against Pseudomonas aeruginosa in Bronchiectasis.
    Am J Respir Crit Care Med. 2024 May 23. doi: 10.1164/rccm.202405-0974.
    PubMed    
    
    
    
39. LONG MB, Gilmour A, Kehl M, Tabor D, et al
    A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of Pseudomonas aeruginosa in Patients with Bronchiectasis.
    Am J Respir Crit Care Med. 2024 May 16. doi: 10.1164/rccm.202308-1403.
    PubMed     Abstract available
    
    
    
40. MARTINEZ-GARCIA MA
    The Heterogeneous World of Non-Tuberculous Mycobacteria in Bronchiectasis.
    Am J Respir Crit Care Med. 2024 May 15. doi: 10.1164/rccm.202405-0936.
    PubMed    
    
    
    
41. GILMORE A, Ortiz J
    Pneumococcal Vaccines.
    Am J Respir Crit Care Med. 2024;209:P5-P7.
    PubMed    
    
    
    
42. LI L, Henkle E, Youngquist BM, Seo S, et al
    Serum Cell-Free DNA-based Detection of Mycobacterium avium Complex Infection.
    Am J Respir Crit Care Med. 2024;209:1246-1254.
    PubMed     Abstract available
    
    
    
43. MCSHANE PJ, Brunton AE, Choate R, Marmor M, et al
    The Impact of Tobacco Smoking in Bronchiectasis: Data from the United States Bronchiectasis and NTM Research Registry.
    Am J Respir Crit Care Med. 2024 May 7. doi: 10.1164/rccm.202402-0466.
    PubMed    
    
    
    
44. DAVIES GR
    Reconsidering the Role of Isoniazid in Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2024 May 1. doi: 10.1164/rccm.202403-0628.
    PubMed    
    
    
    April 2024
45. MATHEMA B, Burzynski J
    One Half of the Pair: Prioritizing Tuberculosis Transmitters for Early Detection.
    Am J Respir Crit Care Med. 2024 Apr 30. doi: 10.1164/rccm.202404-0699.
    PubMed    
    
    
    
46. AKSAMIT TR, Locantore N, Addrizzo-Harris D, Ali J, et al
    Five-Year Outcomes Among U.S. Bronchiectasis and Nontuberculous Mycobacterial Registry Patients.
    Am J Respir Crit Care Med. 2024 Apr 26. doi: 10.1164/rccm.202307-1165.
    PubMed     Abstract available
    
    
    
47. DRAIN PK
    Another Step Closer to Genomic-informed Therapeutic Dosing for Tuberculosis Drugs.
    Am J Respir Crit Care Med. 2024 Apr 22. doi: 10.1164/rccm.202403-0566.
    PubMed    
    
    
    
48. GAUSI K, Ignatius EH, De Jager V, Upton C, et al
    High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.
    Am J Respir Crit Care Med. 2024 Apr 2. doi: 10.1164/rccm.202311-2004.
    PubMed     Abstract available
    
    
    
49. ZHANG M, Luo Q, Li X, Mu X, et al
    Pulmonary Artery Pseudoaneurysm Caused by Pulmonary Mucormycosis.
    Am J Respir Crit Care Med. 2024;209:879-880.
    PubMed    
    
    
    March 2024
50. AHMAD S, Wrennall JA, Goriounova AS, Sekhri M, et al
    Specific Inhibition of Orai1-mediated Calcium Signalling Resolves Inflammation and Clears Bacteria in an Acute Respiratory Distress Syndrome Model.
    Am J Respir Crit Care Med. 2024;209:703-715.
    PubMed     Abstract available
    
    
    
51. VERMA R, Silva KED, Rockwood N, Wasmann RE, et al
    A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
    Am J Respir Crit Care Med. 2024 Mar 5. doi: 10.1164/rccm.202309-1583.
    PubMed     Abstract available
    
    
    February 2024
52. TREVISI L, Brooks MB, Becerra MC, Calderon RI, et al
    Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.
    Am J Respir Crit Care Med. 2024 Feb 28. doi: 10.1164/rccm.202307-1217.
    PubMed     Abstract available
    
    
    January 2024
53. MAC AOGAIN M, Xaverius Ivan F, Jaggi TK, Richardson H, et al
    Airway 'Resistotypes' and Clinical Outcomes in Bronchiectasis.
    Am J Respir Crit Care Med. 2024 Jan 25. doi: 10.1164/rccm.202306-1059.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bacterial Infections and Mycoses is free of charge.